Additional Supporting Information may be found in the online version of this article.

sc-12-0761_sm_SupplFigure1.pdf297KFigure S1 Generation of transgenic murine embryonic stem cells overexpressing FHL2. Schematic representation of the analysis of positive clones in transfected double transgenic αMHC-GFP/αMHCNeoR ESCs. Selected clones (8, 7 and 6) were analyzed by southern blot, qPCR and Western blot. (A): Restriction enzymes used for the generation of the antisense riboprobes using the pCS-MT-FHL2 expressing plasmid for Southern blot analysis. (B): Southern blot detection using the riboprobes described in A. Note the presence of multiple copies in the clone 8, which was used in this study as FHL2-overexpressing ESC line. (C): QPCR showing significant up-regulation of Fhl2 transcripts level in the transgenic cell line. Relative mRNA levels were normalized to Gapdh (D): Western blot analysis confirming up-regulation of FHL2 expression in the transgenic line. GAPDH was used as loading control.
sc-12-0761_sm_SupplFigure2.pdf199KFigure S2 FHL2 accelerates reduction in gene expression of undifferentiated cardiogenic cells in ESC-EBs. FHL2 gain-of-function in ESC-EBs resulted in a reduction of the pluripotent gene Oct4, the panmesodermal, and cardiac mesodermal markers Brachyury and Mesp1, respectively, following 7 days of differentiation in comparison to wild-type cells as shown by qPCR. Relative mRNA levels were normalized to Gapdh. Data represent mean ± SEM; n=6, ** p<0.01, *** p<0.001 (two-tailed Student's t-test).
sc-12-0761_sm_SupplFigure3.pdf211KFigure S3 Inhibition of β-catenin-dependent transcription rescues cardiac differentiation in FHL2-ESCEBs. Quercetin (QC) treatment from day 9 of differentiation completely reversed the decrease in αMHC-GFP expression in differentiating FHL2-ESC-EBs (red triangles and discontinuous lines) in comparison to untreated FHL2-ESC-CMs (red dots and continuous lines). αMHC-GFP expression in FHL2-ESC-EBs upon quercetin reaches similar levels of expression as in untreated control ESC-EBs (black dots and continuous lines). αMHC-GFP expression was calculated as percentages of total EBs. Data represent mean ± SEM; n=10, ** p<0.01, *** p<0.001 (two-tailed Student's t-test).
sc-12-0761_sm_SupplFigure4.pdf349KFigure S4 Transient overexpression of FHL2 enhances β-catenin transcriptional activity while promoting cardiogenesis in P19 cells. (A): FHL2 expression in transiently transfected (FHL2), empty vector transfected (CT) as well as undifferentiated (undiff) pluripotent P19 cells shown by Western blot. (B): Nuclear β-catenin accumulation upon FHL2 transient overexpression. Immunoblot of β-catenin in cytosolic and nuclear fractions showing β-catenin nuclear accumulation in FHL2-P19 cells. Semiquantification via densitometric analysis in 3 independent experiments. Normalization was performed with α.tubulin for the cytosolic fraction and Histone H1 for the nuclear fraction. (C): qPCR analysis of an early cardiogenic specification marker Alpk3, and an early cardiogenic marker Mef2a showing increased expression in FHL2-P19 transient-expressing cells at 2 days of differentiation. (D): Up-regulation of the cycling gene Cyclin D1 normalized to Gapdh expression at 2 days of differentiation in FHL2-P19 transiently expressing cells in comparison to CT P19 cells. (E): KI67 (red) expression analyzed by confocal immunofluorescence (percentage of total DAPI positive cells) following 2 days of differentiation demonstrating increased KI67 cell number in FHL2-P19 cells. Representative pictures are depicted. (F): Significantly decreased expression of Brachyury, Flk1 and Mesp1 as determined by qPCR analysis normalized to Gapdh expression at 10 days of differentiation in FHL2-P19 cells. Data represent mean ± SEM; A and B: n=3, C-F: n=6, two-tailed Student's t-test; * p<0.05; ** p<0.01; *** p<0.001. Scale bar: 10 μm.
sc-12-0761_sm_SupplTable1.pdf302KTable S1: List of primers used in this study. NCBI reference sequence, primer positions, generated fragment length and annealing temperatures are provided.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.